Eli Lilly and Company (Lilly) announced the launch of HumaPen Luxurat HD, an easy-to-use insulin delivery device for patients who may require the precision of half-unit dosing (HD). The new dosing feature enhances safety and accuracy in maintaining glycemic control for patients, especially children with diabetes.

Luxurat HD, a re-usable pen, delivers 0.5 to 30 units of insulin in half-unit increments, and is for use with Lilly insulins humalog (insulin lispro) or huminsulin (insulin human). The device comes with a unique dosing dial that can be moved forward as well as backward, without the loss of insulin.

According to the International Diabetes Federation (IDF), in 2010, approximately 3.80 lakh children in India between the age group 0 to 14years are projected to be suffering with type 1 diabetes. Living with this medical condition poses an enormous challenge for every member of the family. Now with the assurance of half unit dose provided by Luxurat HD, these patients would get the much needed medical and emotional support in their journey for successful management of this disease.

“For children with type 1 diabetes, their journey can often be overwhelming and difficult to manage. We are pleased to introduce Luxurat HD which provides type 1 patients with the confidence and assurance of an accurate delivery of insulin,” said Sandeep Gupta, CMD, Eli Lilly.

Indianapolis headquartered Lilly is a leading innovation-driven corporation developing a growing portfolio of pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organisations.